title: Retropharyngeal lymph node infection in horses: 46 cases (1977-1992).
abstract: A retrospective study of 46 horses with retropharyngeal lymph node (RPLN) infection presented to the Rural Veterinary Centre between 1977 and 1992 was undertaken. Horses aged less than one year were most commonly represented (46%). Thirty-nine percent of cases had been exposed to horses with confirmed or suspected strangles (Streptococcus equi subsp equi infection) within the previous 8 weeks. Most frequent signs were unilateral or bilateral swelling of the throat region (65%), respiratory stertor/dyspnoea (35%), purulent nasal discharge (20%), inappetence and signs of depression (15%), and dysphagia (9%). All horses had a soft tissue density in the retropharyngeal region on radiographs. Rhinopharyngoscopy, ultrasonography, haematology as well as cytological and microbial analysis of material aspirated from the soft tissue swelling facilitated diagnosis in some horses. Fifteen horses (33%) were treated with procaine penicillin intramuscularly for 4 to 7 days followed by oral trimethoprim-sulphadimidine for 7 to 14 days. Non-steroidal anti-inflammatory drugs were administered to 6 horses. Four required tracheostomy for severe respiratory distress. The 15 horses treated medically responded to treatment and were discharged from hospital. Three horses (6%) with mild signs received no treatment and recovered uneventfully. Twenty-eight horses (61%) underwent general anaesthesia and surgical drainage of a RPLN abscess. Nineteen received procaine penicillin G for 4 to 7 days. Four of the nine horses that did not receive antibiotic treatment after surgery required further surgical drainage 10 days to 7 weeks after the initial surgery. Limited follow-up information was available for 37 horses.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Animal Health, University of Sydney, Camden, New South Wales.
authors.forename: L C
authors.initials: LC
authors.lastname: Golland
authors.forename: D R
authors.initials: DR
authors.lastname: Hodgson
authors.forename: R E
authors.initials: RE
authors.lastname: Davis
authors.forename: R J
authors.initials: RJ
authors.lastname: Rawlinson
authors.forename: M B
authors.initials: MB
authors.lastname: Collins
authors.forename: S A
authors.initials: SA
authors.lastname: McClintock
authors.forename: D R
authors.initials: DR
authors.lastname: Hutchins
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004322:Drainage / Q000662:veterinary; D004359:Drug Therapy, Combination; D005260:Female; D006734:Horse Diseases / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D006736:Horses; D007273:Injections, Intramuscular / Q000662:veterinary; D008198:Lymph Nodes / Q000382:microbiology*; D008199:Lymphadenitis / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D008297:Male; D010406:Penicillins / Q000627:therapeutic use; D010614:Pharynx; D017703:Retropharyngeal Abscess / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D018502:Streptococcus equi / Q000302:isolation & purification*; D013418:Sulfamethazine / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
chemical_list: D010406:Penicillins; D013418:Sulfamethazine; D014295:Trimethoprim